Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Indazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.95 |
| ▸ | IDO1 | P14902 | 1/20 | 0.95 |
| ▸ | CDK2 | P24941 | 1/20 | 0.95 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.79 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.53 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.53 |
| ▸ | CLK1 | P49759 | 1/20 | 0.53 |
| ▸ | CLK2 | P49760 | 1/20 | 0.53 |
| ▸ | CLK3 | P49761 | 1/20 | 0.53 |
| ▸ | GSK3B | P49841 | 1/20 | 0.53 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.53 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.53 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.53 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.53 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.53 |
| ▸ | NOS1 | P29475 | 7/20 | 0.48 |
| ▸ | METAP2 | P50579 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indazole SCHEMBL30441881 | 1.00 | HSP90AA1 (0.95) | HSP90AA1IDO1CDK2ABCB1DYRK1A | |
| Indazole SCHEMBL6295 | 0.97 | — | — | |
| Indazole SCHEMBL29355507 | 0.97 | — | — | |
| Indazole SCHEMBL1221882 | 0.97 | HSP90AA1 (1.00) | HSP90AA1IDO1CDK2ABCB1DYRK1A | |
| Indazole SCHEMBL9407408 | 0.95 | HSP90AA1 (0.95) | HSP90AA1IDO1CDK2ABCB1DYRK1A | |
| Indazole SCHEMBL7371212 | 0.95 | HSP90AA1 (0.95) | HSP90AA1IDO1CDK2ABCB1DYRK1A | |
| Indazole SCHEMBL31061369 | 0.95 | HSP90AA1 (0.95) | HSP90AA1IDO1CDK2ABCB1DYRK1A | |
| Indazole SCHEMBL5420749 | 0.95 | HSP90AA1 (0.95) | HSP90AA1IDO1CDK2ABCB1DYRK1A | |
| Indazole SCHEMBL21058156 | 0.95 | HSP90AA1 (0.95) | HSP90AA1IDO1CDK2ABCB1DYRK1A | |
| Indazole SCHEMBL3540508 | 0.95 | HSP90AA1 (0.95) | HSP90AA1IDO1CDK2ABCB1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102803442-A | Method for removing metals from hydrocarbons | PETROLIAM NASIONAL BERHAD | 2012-11-28 | — | — | CN | claimed |
| EP-4688788-A1 | PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS | Pfizer Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12281127-B2 | Pyrido[4,3-d]pyrimidine compounds | PFIZER INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-20250034173-A1 | PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS | PFIZER INC. (US) | 2025-01-30 | — | — | US | disclosed |
| US-20240336631-A1 | Pyrido[4,3-d]pyrimidine Compounds | PFIZER INC. (US) | 2024-10-10 | — | — | US | disclosed |
| WO-2024209339-A1 | PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS | PFIZER INC. (US) | 2024-10-10 | — | — | WO | disclosed |
| CN-102803442-A | Method for removing metals from hydrocarbons | PETROLIAM NASIONAL BERHAD | 2012-11-28 | — | — | CN | disclosed |
| CN-102597277-A | Ionic liquid solvents of the perhalide type for metals and metal compounds | PETROLIAM NASIONAL BERHAD | 2012-07-18 | — | — | CN | disclosed |
| CN-102449204-A | Electrodeposition of elemental zinrconium | ASTRON ADVANCED MATERIALS LTD | 2012-05-09 | — | — | CN | disclosed |
| EP-1828182-A2 | THERAPEUTIC PYRAZOLO[3,4-B]PYRIDINES AND INDAZOLES | Warner-Lambert Company LLC (US) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006056873-A2 | THERAPEUTIC PYRAZOLO[3,4-B] PYRIDINES AND INDAZOLES | WARNER-LAMBERT COMPANY LLC (US) | 2006-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336631-A1 | Pyrido[4,3-d]pyrimidine Compounds | DPYD, PNPO, TYMP | HSP90AA1 4566/4885IDO1 488/4885CDK2 46/4885 |
| US-12281127-B2 | Pyrido[4,3-d]pyrimidine compounds | DPYD, PNPO, TYMP | HSP90AA1 4566/4885IDO1 488/4885CDK2 46/4885 |
| US-20250034173-A1 | PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS | DPYD, PNPO, TYMP | HSP90AA1 4566/4885IDO1 488/4885CDK2 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.